Factor V Leiden Mutation: Nursing Guide
Factor V Leiden is the most common inherited thrombophilia: a change in the F5 gene makes factor V resistant to inactivation by activated protein C, raising lifetime venous thromboembolism risk — especially with pregnancy, surgery, estrogen therapy, or immobility. Nurses prevent harm by confirming appropriate ordering, avoiding “positive gene equals active clot” language, coordinating genetics or haematology follow-up, and escalating new leg swelling, chest pain, or dyspnoea clinically.
Contents
Quick Facts
Key Takeaway
A positive Factor V Leiden result raises lifetime clot risk but does not diagnose active DVT or PE today — and most carriers never develop thrombosis.
Gene & Method Details
Nurse quick-reference for specimen routing, consent context, and result handoff.
F5 (coagulation factor V) — G1691A (factor V Leiden) variant
DNA genotyping (PCR or sequencing) and/or functional activated protein C resistance assay — specific platform varies by laboratory
Peripheral blood (EDTA) or approved saliva/buccal kit
Autosomal dominant (germline)
Commonly days to several weeks depending on referral laboratory — not specified as a single universal turnaround in reviewed references
Germline (inherited) thrombophilia testing
Recommended when results may change anticoagulation duration, hormone choices, or family screening per institutional genetics or haematology policy
What is Factor V Leiden Mutation?
Factor V Leiden Mutation detects the factor V Leiden variant (G1691A) in the F5 gene — also called hereditary resistance to activated protein C, Leiden type. Factor V is a clotting protein normally switched off by activated protein C (APC); the Leiden mutation slows that inactivation, prolonging clot formation. Testing may use DNA analysis or an APC-resistance assay with confirmatory genotyping.
Overview
Nurses support Factor V Leiden testing during thrombophilia workups after deep vein thrombosis, pulmonary embolism, unusual-site venous thrombosis, strong family history, or when hormone therapy decisions need inherited risk context. standard clinical references Genetics notes it is the most common inherited thrombophilia in populations of European ancestry.
Heterozygous carriers (one copy) have moderately increased lifetime VTE risk; homozygous carriers (two copies) have substantially higher risk, though only about 10% of people with the mutation develop abnormal clots. Other risks — obesity, surgery, smoking, pregnancy, and estrogen-containing contraceptives or HRT — stack with the genotype. ASH 2023 guidelines emphasize selective thrombophilia testing when results would change management, not routine panels on every clot.
Before collection, verify the indication matches institutional thrombophilia criteria, document personal and family VTE history, and confirm whether DNA or APC-resistance testing is ordered. After results, teach that genetics informs long-term risk and prevention planning — it does not replace acute pathways for leg swelling, chest pain, or shortness of breath. Escalate acute symptoms according to facility policy while send-out genetics is pending.
Thrombophilia Result Communication and VTE Safety
Factor V Leiden results change long-term thrombosis conversations for patients and families. Treating heterozygosity as an active clot — or dismissing homozygosity before hormone review — can cause delayed VTE care or unsafe estrogen exposure. Nurses protect patients with accurate risk language, acute symptom teaching, and timely specialist follow-up.
- Acute leg swelling or chest pain deferred because genetics is pending
- Homozygous result with estrogen contraceptive or HRT started without haematology review
- Patient told a positive gene confirms active PE or DVT today
- Positive result communicated without thrombophilia follow-up or family screening plan
Document: indication, counseling status, family VTE history, specimen details, zygosity, hormone therapy, notifications, acute symptom teaching, and haematology/genetics referral.
What Factor V Leiden Testing Can and Cannot Tell You
This test can help identify:
- Inherited factor V Leiden (G1691A) with APC resistance when appropriately ordered
- Heterozygous vs homozygous carrier status to inform lifetime VTE risk discussions
- Relatives at risk when cascade testing is offered per haematology or genetics protocol
- Need for combined review of hormones, pregnancy, surgery prophylaxis, and anticoagulation duration
This test cannot:
- Diagnose acute deep vein thrombosis or pulmonary embolism by itself — use acute VTE pathways
- Replace clinical assessment, Wells score, D-dimer, or imaging where indicated
- Rule out all thrombophilia when negative — other genes and acquired causes may remain
- Determine anticoagulation duration or hormone choices alone — requires specialist decisions
Pre-test Checks Before Factor V Leiden Draw
Verify
Clarify before proceeding when:
- Order is routine on acute admission without thrombophilia criteria
- Patient has unilateral leg swelling, chest pain, or dyspnoea today
- Counseling or consent missing when results affect family and hormone decisions
- Estrogen therapy ordered without haematology input in known homozygous carrier
- Known familial variant exists but generic screening without targeted testing is ordered
- Saliva kit instructions not reviewed (eating, rinsing, labeling)
- Team plans to defer acute VTE workup until genetics returns
Heterozygous vs Homozygous Results and VTE Context
Pair Factor V Leiden zygosity with hormone exposure, pregnancy plans, surgery, immobility, obesity, smoking, and concurrent thrombophilia results. Heterozygous carriers have moderate lifetime risk; homozygous carriers have higher risk — yet most mutation carriers never develop clots.
| Clinical context | Pair with Factor V Leiden | Nursing focus |
|---|---|---|
| Heterozygous, no acute symptoms | Positive G1691A, one copy | Balanced risk teaching; haematology follow-up; family screening per protocol |
| Homozygous carrier | Two copies of variant | Urgent specialist review; scrutinize estrogen and surgery prophylaxis plans |
| Negative DNA, strong family history | Wild-type F5 on panel | Notify team — other thrombophilias or familial variants may still apply |
| New leg swelling during testing wait | Any genetic status | Escalate acute VTE pathway — do not wait for molecular results |
On a small screen, swipe or scroll sideways to see the full table.
Risk vs Diagnosis Language at the Bedside
| Bedside point | Nursing note |
|---|---|
| Risk vs diagnosis | Never chart that genetics alone confirms active DVT or PE |
| Zygosity matters | Homozygous results warrant tighter hormone and prophylaxis review than heterozygous |
| Not a stat VTE test | Send-out DNA does not rule in or out PE today — escalate symptoms clinically |
| Estrogen trap | Document combined oral contraceptives and HRT — carriers need specialist hormone counseling |
| Family conversations | Cascade screening needs counseling; avoid pressuring relatives at the bedside |
| Panel context | Interpret Factor V Leiden with protein C/S, lupus anticoagulant, and prothrombin results when ordered |
On a small screen, swipe or scroll sideways to see the full table.
The clarify / hold rule
Clarify before proceeding when:
- Indication does not match institutional thrombophilia criteria
- Acute VTE symptoms are present or worsening
- Counseling or consent is incomplete for a test affecting family and hormones
- Homozygous result on chart but estrogen therapy is newly ordered
- Patient cannot describe acute symptoms that require urgent reporting
- Saliva kit or blood specimen labeling mismatch
- Positive result has no haematology or genetics follow-up scheduled
Factor V Leiden in Thrombophilia Pathways
Diagnostic safety badge: Routine diagnostic test — standard identification, preparation, and result-follow-up checks still apply; positive genetics may require specialist follow-up and family counseling.
Check-before-test protocol
- Identity + indication + thrombophilia criteria
- Family VTE and hormone history documented
- Counseling or consent when required
- Acute VTE symptom screen
- Correct specimen collection and labeling
Critical teach-back questions
- “Can you tell me why we are checking for Factor V Leiden?”
- “What is the difference between a positive gene result and having a clot right now?”
- “What leg or chest symptoms should you report before the result comes back?”
Care coordination: prescriber, haematology, genetics counselor, laboratory, anticoagulation clinic, obstetrics when relevant, and rapid response per institutional protocol.
Factor V Leiden Testing Quick Safety Checklist
- Does this order meet thrombophilia testing criteria?
- Did I teach acute VTE symptoms independent of pending genetics?
- Is zygosity documented and routed to the right specialist?
- Are estrogen or hormone plans reviewed for homozygous or high-risk carriers?
- Who must be notified about a positive or unexpected result?
Why Factor V Leiden Mutation is Ordered
Factor V Leiden testing is ordered when clinicians need to assess inherited thrombophilia as part of a hypercoagulability evaluation — typically when results may influence anticoagulation duration, prophylaxis, hormone counseling, or family screening.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Recurrent or unexplained venous thromboembolism | Does an inherited thrombophilia change long-term management? | Selective thrombophilia testing may be appropriate when results would alter anticoagulation or prophylaxis decisions per ASH 2023 and institutional pathways. |
| First VTE at young age, unusual site, or strong family history | Should moderate-risk thrombophilia be identified? | Factor V Leiden is a common inherited cause of APC resistance; family history may prompt testing of relatives when results could change hormone or prophylaxis choices. |
| Preconception or contraception counseling with personal/family thrombosis history | Will genotype affect estrogen exposure or pregnancy planning? | standard clinical references Genetics and GeneReviews note estrogen therapy and pregnancy increase risk in carriers; genetics or haematology interprets combined risk. |
| Evaluation of recurrent pregnancy loss when thrombophilia workup is ordered | Is inherited thrombophilia part of the ordered panel? | Association with pregnancy loss is reported but not fully confirmed for all complications — testing should follow specialist-directed protocols, not bedside interpretation alone. |
Contraindications and Precautions
There is no absolute contraindication to DNA collection itself. Testing may be inappropriate during acute thrombosis workup when immediate management will not change, or without counseling when results affect family members and hormone decisions.
- New unilateral leg swelling, pain, warmth, or redness — initiate VTE pathway per prescriber; do not wait for Factor V Leiden results.
- Acute chest pain, pleuritic pain, dyspnoea, tachycardia, or hypoxia suggesting PE.
- Telling a patient with VTE symptoms that a negative pending genetic test rules out clot.
- Positive heterozygous result — moderate lifetime risk; most carriers never clot.
- Homozygous result — higher risk; still requires clinical context and specialist plan.
- Negative DNA test does not exclude all thrombophilia — prothrombin G20210A, antiphospholipid syndrome, and acquired causes may still be present.
- Acute VTE signs or symptoms while genetics pending — escalate per facility policy.
- Homozygous Factor V Leiden with new hormone prescription — notify prescriber/haematology before administration when policy requires.
- Positive result without documented follow-up for anticoagulation or family counseling plan.
Patient Preparation
Preparation focuses on order verification, family history, counseling when required, and correct specimen labeling — not fasting for standard germline DNA blood draws unless combined tests require it.
Pre-test checksReview estrogen-containing contraceptives, hormone replacement therapy, selective estrogen receptor modulators, and current anticoagulants (warfarin, heparin, direct oral anticoagulants). Do not stop prescribed medicines without prescriber authorization — document therapy for interpretation.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Factor V Leiden Mutation. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Results are typically reported as factor V Leiden detected (heterozygous or homozygous) or not detected on DNA testing. APC-resistance assays may screen before confirmatory genotyping. Nurses record the classification reported and route interpretation to haematology or genetics — not independent changes to anticoagulation or hormones.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Negative / not detected | Factor V Leiden (G1691A) not detected / wild-type F5 | No inherited factor V Leiden variant identified on the performed assay — does not exclude other thrombophilias or acquired hypercoagulability | Interpret with full thrombophilia panel and clinical history; continue VTE prevention per risk factors |
| Equivocal / borderline | Equivocal APC-resistance ratio pending confirmatory DNA | Screening assay inconclusive — may reflect assay variation, acute illness, or laboratory-specific cutoffs | Hold bedside conclusions; ensure confirmatory F5 genotyping per laboratory protocol |
| Positive / elevated | Factor V Leiden detected — heterozygous (one copy) | Inherited APC resistance with moderately increased lifetime VTE risk; risk rises with estrogen therapy, pregnancy, surgery, and immobility Genetics | Notify prescriber/haematology per protocol; support counseling on hormones, pregnancy, and family screening; teach acute VTE symptoms |
| Not applicable / below detection limit | Factor V Leiden detected — homozygous (two copies) | Substantially higher thrombosis risk than heterozygous state; still not a diagnosis of active clot today | Urgent haematology/genetics follow-up per protocol; review estrogen exposure and prophylaxis plans; document family cascade counseling referral |
Acute VTE Urgency With Pending Genetics
Factor V Leiden is not reported as a numeric critical laboratory value. Clinical urgency is driven by acute thrombosis symptoms, homozygous results with high-risk exposures, and failure to communicate positive results to appropriate specialists.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Acute VTE symptoms with any genetic status | Leg swelling, pain, chest pain, dyspnoea, tachycardia, or hypoxia | Escalate according to facility policy — use acute VTE imaging and treatment pathways; do not defer for pending Factor V Leiden |
| Homozygous result with planned estrogen therapy | Two copies of factor V Leiden; estrogen contraceptive or HRT ordered | Notify prescriber and haematology/genetics before hormone administration per protocol |
| Positive genetics without specialist follow-up | Heterozygous or homozygous result; no haematology or counseling appointment | Coordinate follow-up and document notification; evaluate outcomes after management plan is set |
Escalate according to facility policy when the patient develops symptoms suggesting acute venous thromboembolism, when a homozygous result is paired with high-risk hormone exposure, or when positive genetics has not been communicated within the timeframe defined by your thrombophilia service.
Factors Affecting Results
Factor V Leiden interpretation depends on zygosity, acquired risks, and test method. Nurses prevent harm by avoiding single-result conclusions and documenting clinical context.
- APC-resistance assay positive without confirmatory DNA in some acute or inflammatory states
- Sample mix-up or mislabeling — rare but high-impact; always verify identifiers
- Assuming positive genetics explains a current clot without imaging when pre-test probability is low
- DNA negative while other thrombophilias present — e.g., prothrombin G20210A or lupus anticoagulant
- Testing only factor V Leiden when a broader thrombophilia panel was clinically indicated
- Reassuring patient with strong symptoms because genetics is negative
- Acute thrombosis, inflammation, or pregnancy — may affect some functional assays
- Recent transfusion or transplant — may affect blood DNA source
- Incomplete family history leading to wrong test (screening vs familial variant testing)
Factor V Leiden testing alone does not diagnose active DVT or PE and cannot replace clinical assessment or imaging. ASH 2023 generally recommends against broad thrombophilia testing in many VTE scenarios when results will not change management. Negative results do not eliminate clot risk from acquired factors. Management should follow haematology and genetics guidance — not nursing interpretation alone.
Nursing Responsibilities
Nursing care emphasizes appropriate ordering support, accurate specimen handling, balanced risk communication, acute symptom monitoring, and coordination with haematology or genetics for hormone and family decisions.
Before the TestDocumentation
Documentation should capture indication, family history, specimen details, result zygosity, notifications, and teaching without implying independent genetic diagnosis.
“Factor V Leiden DNA specimen collected 10:15 — lavender EDTA tube, two identifiers verified, sent to molecular laboratory. Indication: prior unprovoked DVT age 31; father with PE at 45. Patient on no estrogen therapy; apixaban completed 8 weeks ago. Genetics counseling completed yesterday. Pending result; taught to report unilateral leg swelling, chest pain, or sudden breathlessness immediately.”
- Indication, order type (DNA vs APC resistance), and counseling/consent status
- Personal and family VTE history, hormone therapy, pregnancy status
- Specimen type, collection time, labeling, and transport
- Result (not detected, heterozygous, homozygous) with laboratory nomenclature
- Prescriber/haematology notification and patient teaching provided
- Family screening referral and follow-up appointment details
Patient and Family Education
Patients often equate a “clotting gene” with an immediate emergency. Use calm, accurate language: the test clarifies inherited risk to guide prevention and family conversations.
Factor V Leiden Mutation NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Factor V Leiden Mutation safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Factor V Leiden DNA genotyping — thrombophilia panel
- Indication: 32-year-old with prior unprovoked DVT; mother heterozygous for factor V Leiden
- Timing: Collected today — 9 weeks after completing anticoagulation per protocol
- Related orders: Protein C, protein S, lupus anticoagulant screen; prothrombin G20210A per protocol
- Result: Factor V Leiden heterozygous (G1691A) detected; APC-resistance not separately ordered
- Trend / prior value: No prior genetic testing; acute-phase D-dimer elevated during admission (resolved)
- Pending tests: Haematology telehealth Thursday; family screening pamphlet requested; no estrogen contraceptive planned
- Vital signs: HR 76/min, BP 116/70, RR 15/min, SpO₂ 99% on room air, temp 36.8°C
- Symptoms: No leg pain or dyspnoea; worried about “passing gene to daughter”
- Focused assessment: Calves symmetric, lungs clear; mobility normal; combined oral contraceptive stopped after DVT
- Preparation notes: Counseling documented; consent signed; EDTA tube labeled; patient asked if result means active clot
- Collection events: Venipuncture tolerated; specimen accepted by laboratory
- Teaching gaps / safety concerns: Risk of alarmist teaching; needs balanced heterozygous risk language and acute symptom plan
Answer key & rationale
Frequently Asked Questions
FAQ
What is Factor V Leiden?
It is a specific F5 gene change (G1691A) that makes coagulation factor V resistant to inactivation by activated protein C, increasing tendency to form abnormal clots. It is the most common inherited thrombophilia in many populations Genetics.
Does a positive Factor V Leiden result mean the patient has a clot now?
No. The test identifies inherited risk. Only about 10% of people with the mutation develop abnormal clots over life, and acute VTE requires clinical assessment and imaging — not genetics alone.
What is the difference between heterozygous and homozygous results?
Heterozygous means one copy of the variant (moderately increased lifetime VTE risk). Homozygous means two copies (substantially higher risk). Exact management is set by haematology or genetics with the full clinical picture.
Should every patient with one DVT receive Factor V Leiden testing?
Not routinely. ASH 2023 guidelines conditionally recommend against broad thrombophilia testing in many VTE scenarios and support selective testing when results would change management — such as strong family history or unusual presentations.
How do estrogen contraceptives interact with Factor V Leiden?
standard clinical references Genetics and GeneReviews note estrogen-containing contraceptives and HRT increase clot risk, especially in carriers. Hormone decisions require prescriber and specialist input — nurses document therapy and escalate when high-risk combinations are ordered without review.
Is fasting required before Factor V Leiden testing?
Usually no special preparation is required for DNA blood draws. Saliva kits have specific restrictions — follow the kit and laboratory instructions. Fast only if other tests on the same draw require it.
When should nurses escalate before genetic results return?
Escalate according to facility policy if the patient develops new unilateral leg swelling, pain, warmth, redness, chest pain, dyspnoea, tachycardia, or hypoxia — these may indicate acute VTE regardless of pending Factor V Leiden results.
References
References
-
U.S. National Library of Medicine. Factor V Leiden thrombophilia. MedlinePlus Genetics.https://medlineplus.gov/genetics/condition/factor-v-leiden-thrombophilia/
-
Pastori D; Menichelli D; Valeriani E; Pignatelli P. Factor V Leiden Thrombophilia. GeneReviews. NIH Bookshelf; updated 2024.https://www.ncbi.nlm.nih.gov/books/NBK1368/
-
Grody WW; Griffin JH; Taylor AK; Korf BR; Heit JA; ACMG Factor V. Leiden Working Group. ACMG consensus statement on factor V. Leiden mutation testing. Genet Med. 2001.https://pubmed.ncbi.nlm.nih.gov/11261526/
-
American Society of Hematology. 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023.https://pmc.ncbi.nlm.nih.gov/articles/PMC10709681/
-
Rosendorff A; Dorfman DM. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med. 2007.https://pubmed.ncbi.nlm.nih.gov/17516736/
-
Segal JB; Brotman DJ; Necochea AJ; et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism. JAMA. 2009.https://pubmed.ncbi.nlm.nih.gov/19531785/
-
Horne MK 3rd; McCloskey DJ. Factor V Leiden as a common genetic risk factor for venous thromboembolism. J Nurs Scholarsh. 2006.https://pubmed.ncbi.nlm.nih.gov/16498715/
-
National Library of Medicine. Genetic Testing Registry: Thrombophilia due to activated protein C resistance. NIH.https://www.ncbi.nlm.nih.gov/gtr/tests/11877/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Factor V Leiden Mutation.
Policies: Medical Review Process · Editorial Policy · Correction Policy